FIELD: medicine.
SUBSTANCE: group of inventions relates to a method for cancer treatment or prevention where the cancer cells express CLDN18.2, comprising administration of an antibody with an ability to bind to CLDN18.2, in combination with a γδ T cells stimulator and interleukin-2, where the γδ T cells stimulator is bisphosphonate. The group of inventions also relates to a medical preparation for treatment or prevention of a cancerous disease comprising the said substances; a kit for cancer treatment or prevention.
EFFECT: significant increase in total ADCC activity.
35 cl, 26 dwg, 1 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2014 |
|
RU2678700C2 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
| ANTIBODIES TO BTN3A AND THEIR USE IN THE TREATMENT OF CANCER OR INFECTIOUS DISEASES | 2019 |
|
RU2800726C2 |
